FIRST DATA CORPORATION (NSE:FDC) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendment to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
Certificate of Retirement with the Secretary of State of the
State of Delaware to retire 175,001,996 shares of Class B Common
Stock, par value $0.01 per share, of First Data (Class B Common
Stock). All 175,001,996 shares of Class B Common Stock were
converted into shares of Class A Common Stock, par value $0.01
per share, of First Data (Class A Common Stock). First Datas
Amended and Restated Certificate of Incorporation requires that
any shares of Class B Common Stock that are converted into shares
of Class A Common Stock be retired and may not be reissued.
Amended and Restated Certificate of Incorporation of First Data
to reduce the total number of authorized shares of capital stock
of First Data by 175,001,996 shares. The total number of
authorized shares of First Data is now 2,324,998,004 shares,
consisting of 1,600,000,000 shares designated Class A Common
Stock, 624,998,004 shares designated Class B Common Stock, and
100,000,000 shares designated preferred stock, $0.01 par value
per share. A copy of the Certificate of Retirement is attached as
Exhibit 3.1 hereto.
its 6.75% Senior Secured Notes due 2020 that First Data intends
to redeem $1 billion of the notes on January 24, 2017. First
Datas obligation to pay the redemption amount is conditioned upon
consummation of a debt financing to be offered following the date
of the notice that yields net proceeds that are sufficient to pay
the redemption amount. The condition may be waived by First Data
in its sole discretion. This Form 8-K does not constitute a
notice of redemption.
report.
|
Exhibit No
|
Description of Exhibit
|
|
3.1
|
Certificate of Retirement of 175,001,996 Shares of
Class B Common Stock |
About FIRST DATA CORPORATION (NSE:FDC)
FDC Limited is a pharmaceutical company. The Company is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS). Its therapeutic areas of focus include anti-infectives, gastrointestinals, ophthalmologicals, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology and analgesics. It has a range of functional foods and beverages. Its active pharmaceuticals ingredients (APIs) produced cover a range of therapeutic categories, such as Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate. Its brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm. It has multi-location manufacturing facilities for APIs, as well as finished dosage forms. Its facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FIRST DATA CORPORATION (NSE:FDC) Recent Trading Information
FIRST DATA CORPORATION (NSE:FDC) closed its last trading session up +3.35 at 216.80 with 64,348 shares trading hands.
